Analyst firms · Citigroup · DGX
Citigroup DGX price target and rating history
Quest Diagnostics Incorporated (DGX) · Health Care
Citigroup rates Quest Diagnostics Incorporated (DGX) Neutral with a $185 price target, as of its latest action on Mar 4, 2025. It has published 5 rating actions on DGX since April 2022, including 2 upgrades and 3 downgrades.
- Current rating
- Neutral
- Price target
- $185
- Median target, all firms
- Too few
- Actions on DGX
- 5
Citigroup price target on DGX
Every Citigroup rating on DGX
- Mar 4, 2025
- Jul 10, 2024
- Apr 3, 2023
- Nov 17, 2022
- Apr 4, 2022
Questions about Citigroup and DGX
- What is Citigroup's price target for DGX?
- Citigroup's latest stated price target for Quest Diagnostics Incorporated (DGX) is $185, from its action on Mar 4, 2025.
- What is Citigroup's rating on DGX?
- Citigroup rates DGX Neutral, a neutral rating, as of Mar 4, 2025.
- When did Citigroup last change its view on DGX?
- On Mar 4, 2025, Citigroup downgrades to Neutral from Buy, price target $185.
More DGX rating histories
All Citigroup ratingsDGX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.